DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy

计划入组 406 人 · 首次发布于 2012 年 3 月 27 日

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

计划入组 5,000 人 · 首次发布于 2010 年 1 月 5 日

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

计划入组 1,500 人 · 首次发布于 2020 年 7 月 27 日

SPY-003

SPY-001

Tradr 2X Long SPY Monthly ETF

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

I-SPY 2.2 Trial Design Shows Promise in Identifying Less Toxic Breast Cancer Therapies

I-SPY 2.2 Trial Revolutionizes Breast Cancer Treatment with Patient-Centered Design

Signatera ctDNA Test Predicts Recurrence Risk in High-Risk Breast Cancer Patients, I-SPY 2 Trial Data Shows